SFI
GBT

Susquehanna Fundamental Investments’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-34,400
Closed -$1.9M – 1657
2020
Q3 		$1.9M Hold
34,400
– – 0.06% 448
2020
Q2 		$2.17M Buy
+34,400
New +$2.36M 0.1% 254

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Susquehanna Fundamental Investments's GBT Position: Q4 2020 in Review

Susquehanna Fundamental Investments sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 34,400 shares — an estimated $1.9M sold.

Susquehanna Fundamental Investments first reported a position in GBT in Q2 2020 and held it in 2 quarters. The position peaked at $2.17M in Q2 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

  • Susquehanna Fundamental Investments reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 34,400 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $1.9M.
  • Susquehanna Fundamental Investments first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Global Blood Therapeutics, Inc. position peaked at $2.17M in Q2 2020.
  • 228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2020, filed 16 Feb 2021.